Obstetrics & Gynecology · Medical Literature
Dose-response relationship of prophylactic norepinephrine infusion for prevention of spinal anesthesia-induced hypotension during caesarean delivery: A comparative study of normal weight and obese parturients.
Abstract
Obese parturients are at increased risk of spinal anesthesia-induced hypotension during cesarean delivery, but optimal prophylactic norepinephrine dosing remains unclear. In this randomized, double-blind, dose-response study, 200 parturients undergoing elective cesarean delivery were stratified into obese (BMI ≥30 kg/m²) and normal weight (BMI 18.5-24.9 kg/m²) groups. Within each group, patients received norepinephrine infusion at 0.02-0.06 µg·kg⁻¹·min⁻¹. Standardized combined spinal-epidural anesthesia with 16 mg hyperbaric ropivacaine was used, and infusion was started immediately after spinal injection. Hypotension was defined as SBP 20% decrease from baseline, and success as absence of hypotension. Probit regression was used to estimate ED50 and ED95. ED50 and ED95 were 0.022 (95% CI 0.015-0.029) and 0.051 (0.041-0.061) µg·kg⁻¹·min⁻¹ in normal weight, compared with 0.036 (0.029-0.043) and 0.080 (0.058-0.102) µg·kg⁻¹·min⁻¹ in obese parturients. The relative potency ratio was 1.597 (95% CI 1.007-2.187; P=0.013). Neonatal outcomes and maternal adverse effects were comparable. Obese parturients require higher weight-adjusted norepinephrine infusion rates to prevent spinal anesthesia-induced hypotension during cesarean delivery.
Clinical relevance
In parturients undergoing elective cesarean delivery under combined spinal-epidural anesthesia, what weight-adjusted norepinephrine infusion rates (ED50 and ED95) are required to prevent spinal anesthesia-induced hypotension in obese versus normal-weight women, and are these doses, neonatal outcomes, and maternal adverse effects comparable between BMI groups? __SNAPSHOT__ {"studyDesign":"Randomized, double-blind, dose-response study using probit regression to estimate ED50 and ED95","setting":"Not reported (single or multicenter status not specified in abstract); likely China based on journal context and prior related work","sampleSize":"n=200 parturients (stratified into two groups of 100 each: obese BMI ≥30 kg/m² and normal weight BMI 18.5–24.9 kg/m²); per-dose-arm allocation not reported in abstract","population":"Adult parturients undergoing elective cesarean delivery; stratified by BMI into normal weight (18.5–24.9 kg/m²) and obese (≥30 kg/m²); singleton term pregnancies presumed but not explicitly stated in abstract","intervention":"Prophylactic continuous norepinephrine infusion at weight-adjusted doses of 0.02–0.06 µg·kg⁻¹·min⁻¹, initiated immediately after intrathecal injection of 16 mg hyperbaric ropivacaine via combined spinal-epidural technique","comparator":"Dose-response comparison across dose tiers within each BMI stratum; obese versus normal-weight groups also compared at equivalent infusion rates","primaryOutcome":"Prevention of spinal anesthesia-induced hypotension, defined as SBP 20% decrease from baseline; 'success' defined as complete absence of hypotension","followUp":"Perioperative period (until delivery); exact duration not reported in abstract","fundingSource":"Not reported"}
Key findings
Using probit regression, ED50 and ED95 for hypotension prevention in normal-weight parturients were 0.022 µg·kg⁻¹·min⁻¹ (95% CI 0.015–0.029) and 0.051 µg·kg⁻¹·min⁻¹ (95% CI 0.041–0.061), respectively. In obese parturients, the corresponding values were substantially higher: ED50 0.036 µg·kg⁻¹·min⁻¹ (95% CI 0.029–0.043) and ED95 0.080 µg·kg⁻¹·min⁻¹ (95% CI 0.058–0.102). The relative potency ratio comparing normal-weight to obese parturients was 1.597 (95% CI 1.007–2.187; P=0.013), indicating that obese parturients required approximately 60% higher weight-adjusted norepinephrine infusion rates to achieve equivalent hypotension prevention. The absolute difference in ED50 between groups was 0.014 µg·kg⁻¹·min⁻¹ (calculated) and in ED95 was 0.029 µg·kg⁻¹·min⁻¹ (calculated). Neonatal outcomes and maternal adverse effects were reported as comparable between groups; specific adverse event rates, p-values, and neonatal blood gas data are not reported in the available abstract. NNT and NNH cannot be calculated from the abstract data provided.
Practice implications
This study establishes a statistically significant and clinically plausible dose-response relationship between weight-adjusted norepinephrine infusion rate and prevention of spinal-induced hypotension during cesarean delivery, and demonstrates that obese parturients require meaningfully higher infusion rates than normal-weight counterparts (relative potency ratio ~1.6, P=0.013). The finding that the ED95 in obese parturients (0.080 µg·kg⁻¹·min⁻¹) exceeds the upper dose tier studied (0.06 µg·kg⁻¹·min⁻¹) raises an important concern: the trial's dose range may have been insufficient to fully characterize the upper end of the dose-response curve in obese patients, potentially underestimating the true ED95. The comparable neonatal outcomes and maternal adverse effect profile are reassuring but must be interpreted cautiously given the abstract-only data available and the absence of reported absolute event rates or confidence intervals for safety endpoints. These findings apply specifically to obese and normal-weight elective cesarean patients receiving standardized combined spinal-epidural anesthesia with hyperbaric ropivacaine; generalizability to patients with preeclampsia, emergency cesarean delivery, or other vasopressor regimens is not established. Underweight patients, those with pre-existing cardiovascular disease, and twin gestations were not represented. The statistically significant relative potency ratio suggests practice-informing implications—clinicians should not assume that weight-adjusted norepinephrine dosing provides equivalent hypotension protection across BMI categories—but confirmation in larger trials with a broader dose range and full safety reporting is warranted before firm dosing protocol changes are adopted. Only the abstract was available for review; full manuscript data (including adverse event tables, hemodynamic time series, and neonatal blood gas values) were not accessible. __LIMITATIONS__ Dose range (0.02–0.06 µg·kg⁻¹·min⁻¹) may be insufficient to fully characterize the dose-response curve in obese parturients, as the derived ED95 (0.080 µg·kg⁻¹·min⁻¹) exceeds the maximum dose tested.,Sample size of 100 per BMI stratum, distributed across multiple dose tiers, may limit precision of ED95 estimates, particularly in the obese group where confidence intervals are wide (0.058–0.102).,Abstract does not report absolute incidence of hypotension, hypertension, bradycardia, or reactive hypertension per group, preventing full safety assessment.,Neonatal outcomes described as 'comparable' without reported Apgar scores, umbilical arterial pH values, or statistical comparisons.,Single local anesthetic agent (hyperbaric ropivacaine 16 mg) and a standardized combined spinal-epidural technique; findings may not extrapolate to plain bupivacaine or spinal-only anesthesia.,Setting not reported, limiting assessment of institutional and population generalizability.,BMI stratification uses a binary classification (normal vs. obese ≥30 kg/m²); dose-response within the spectrum of obesity (Class I, II, III) is not characterized.,No comparator vasopressor arm (e.g., phenylephrine); the study does not address whether phenylephrine dosing similarly requires upward adjustment in obese parturients.,Funding source not reported; potential for undisclosed conflicts of interest cannot be assessed.,Only abstract available; full methodology, randomization sequence, allocation concealment, blinding adequacy, and protocol deviations cannot be evaluated. __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ Obese parturients (BMI ≥30 kg/m²) require approximately 60% higher weight-adjusted norepinephrine infusion rates than normal-weight parturients to prevent spinal anesthesia-induced hypotension during cesarean delivery, with a statistically significant relative potency ratio of 1.597 (95% CI 1.007–2.187; P=0.013). The estimated ED95 in obese patients (0.080 µg·kg⁻¹·min⁻¹) exceeds the upper dose boundary tested, and full safety data are not yet available from the abstract alone. Clinicians should consider that standard weight-adjusted dosing protocols derived from normal-weight cohorts likely underprotect obese parturients, but individualized titration with vigilant hemodynamic monitoring is advisable pending confirmation in adequately powered trials with a broader dose range.